The stock of Tourmaline Bio Inc (TRML) has gone down by -11.86% for the week, with a 1.20% rise in the past month and a 2.12% rise in the past quarter. The volatility ratio for the week is 2.72%, and the volatility levels for the past 30 days are 3.74% for TRML. The simple moving average for the last 20 days is -4.64% for TRML stock, with a simple moving average of -13.36% for the last 200 days.
Is It Worth Investing in Tourmaline Bio Inc (NASDAQ: TRML) Right Now?
Additionally, the 36-month beta value for TRML is 2.07. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TRML is 16.37M and currently, short sellers hold a 18.85% ratio of that float. The average trading volume of TRML on June 20, 2025 was 347.24K shares.
TRML) stock’s latest price update
The stock of Tourmaline Bio Inc (NASDAQ: TRML) has decreased by -7.43 when compared to last closing price of 18.18. Despite this, the company has experienced a -11.86% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-20 that Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by 2035.
Analysts’ Opinion of TRML
Many brokerage firms have already submitted their reports for TRML stocks, with Chardan Capital Markets repeating the rating for TRML by listing it as a “Buy.” The predicted price for TRML in the upcoming period, according to Chardan Capital Markets is $70 based on the research report published on April 23, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see TRML reach a price target of $42. The rating they have provided for TRML stocks is “Outperform” according to the report published on March 06th, 2025.
BMO Capital Markets gave a rating of “Outperform” to TRML, setting the target price at $50 in the report published on December 06th of the previous year.
TRML Trading at 2.44% from the 50-Day Moving Average
After a stumble in the market that brought TRML to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.50% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRML starting from Kulkarni Sandeep Chidambar, who purchase 1,779 shares at the price of $14.85 back on Aug 21 ’24. After this action, Kulkarni Sandeep Chidambar now owns 7,000 shares of Tourmaline Bio Inc, valued at $26,418 using the latest closing price.
Kulkarni Sandeep Chidambar, the CEO of Tourmaline Bio Inc, purchase 5,221 shares at $13.79 during a trade that took place back on Aug 16 ’24, which means that Kulkarni Sandeep Chidambar is holding 5,221 shares at $71,998 based on the most recent closing price.
Stock Fundamentals for TRML
Current profitability levels for the company are sitting at:
- -2461.15 for the present operating margin
- 0.25 for the gross margin
The net margin for Tourmaline Bio Inc stands at -2071.72. The total capital return value is set at -0.35. Equity return is now at value -26.14, with -25.63 for asset returns.
Based on Tourmaline Bio Inc (TRML), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -428.67.
Currently, EBITDA for the company is -89.73 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 9930.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 33.87.
Conclusion
In conclusion, Tourmaline Bio Inc (TRML) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
